logo
#

Latest news with #securitiesfraud

Lost Money on Reddit, Inc. (RDDT)? Join Class Action Before August 18, 2025 - Contact Levi & Korsinsky
Lost Money on Reddit, Inc. (RDDT)? Join Class Action Before August 18, 2025 - Contact Levi & Korsinsky

Globe and Mail

time12 hours ago

  • Business
  • Globe and Mail

Lost Money on Reddit, Inc. (RDDT)? Join Class Action Before August 18, 2025 - Contact Levi & Korsinsky

New York, New York--(Newsfile Corp. - July 24, 2025) - If you suffered a loss on your Reddit, Inc. (NYSE: RDDT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against Reddit, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between October 29, 2024 and May 20, 2025. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) changes in Google Search's algorithm and features like AI Overview were causing users to stop their query on Google Search; (ii) these algorithm changes were materially different than prior instances of reduced traffic to the Reddit website; (iii) defendants were aware that the increase in the query term "Reddit" on search engines was because users were getting the sought after answer from Google Search without having to go to Reddit, and not because they intended to visit Reddit; (iv) this zero-click search reality was dramatically reducing traffic to Reddit in a manner the Company was unable to overcome in the short term; (v) defendants, therefore, lacked a reasonable basis for their outlook on user rates and advertising revenues; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in Reddit, Inc. stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

RXST INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
RXST INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Globe and Mail

time14 hours ago

  • Business
  • Globe and Mail

RXST INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The law firm of Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.) – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges certain of RxSight's executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the RxSight class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ Lead plaintiff motions for the RxSight class action lawsuit must be filed with the court no later than September 22, 2025. CASE ALLEGATIONS: RxSight is a commercial-stage medical technology company that engages in the research and development, manufacture, and sale of light adjustable intraocular lenses ('LAL') used in cataract surgery. The RxSight class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) RxSight was experiencing 'adoption challenges' and/or structural issues resulting in declines in sales and utilization; (ii) defendants had overstated the demand for RxSight's products; and (iii) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025. The RxSight class action lawsuit further alleges that on July 8, 2025, RxSight reported preliminary second quarter of 2025 financial results, revealing significant declines in Light Delivery Device ('LDD') sales, LAL utilization, and overall revenue. RxSight also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint, and RxSight's CEO, defendant Ronald Kurtz, disclosed that '[a]doption challenges over the last few quarters have been a primary reason for the LDD stall,' according to the complaint. The RxSight class action lawsuit alleges that on this news, the price of RxSight stock fell nearly 38%. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired RxSight securities during the class period to seek appointment as lead plaintiff in the RxSight class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the RxSight class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the RxSight class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the RxSight class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit with the Schall Law Firm
RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Globe and Mail

timea day ago

  • Business
  • Globe and Mail

RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RxSight, Inc. ('RxSight' or 'the Company') (NASDAQ: RXST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 7, 2024 and July 8, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before September 22, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. RxSight experienced 'adoption challenges' causing declining sales and utilization rates. The Company overstated customer demand for its products. The Company was unlikely to achieve its financial guidance for fiscal year 2025. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about RxSight, investors suffered damages Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Law Offices of Howard G. Smith Encourages RxSight, Inc. (RXST) Investors To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith Encourages RxSight, Inc. (RXST) Investors To Inquire About Securities Fraud Class Action

Globe and Mail

timea day ago

  • Business
  • Globe and Mail

Law Offices of Howard G. Smith Encourages RxSight, Inc. (RXST) Investors To Inquire About Securities Fraud Class Action

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased RxSight, Inc. ('RxSight' or the 'Company') (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025, inclusive (the 'Class Period'). RxSight investors have until September 22, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN RXSIGHT, INC. (RXST), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On July 8, 2025, after the market closed, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in LDD sales, LAL utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. The Company's Chief Executive Officer, Ronald Kurtz, disclosed that '[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.' On this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025, on unusually heavy trading volume. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company was experiencing 'adoption challenges' and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight's products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Contact Us To Participate or Learn More: If you purchased RxSight securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at:

Law Offices of Frank R. Cruz Encourages RxSight, Inc. (RXST) Investors To Inquire About Securities Fraud Class Action
Law Offices of Frank R. Cruz Encourages RxSight, Inc. (RXST) Investors To Inquire About Securities Fraud Class Action

Associated Press

timea day ago

  • Business
  • Associated Press

Law Offices of Frank R. Cruz Encourages RxSight, Inc. (RXST) Investors To Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--Jul 23, 2025-- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased RxSight, Inc. ('RxSight' or the 'Company') (NASDAQ: RXST ) securities between November 7, 2024 and July 8, 2025, inclusive (the 'Class Period'). RxSight investors have until September 22, 2025 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR RXSIGHT, INC. INVESTMENTS, CLICKHERETO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at [email protected], by telephone at (310) 914-5007, or visit our website at What Happened? On July 8, 2025, after the market closed, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in LDD sales, LAL utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. The Company's Chief Executive Officer, Ronald Kurtz, disclosed that '[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.' On this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025, on unusually heavy trading volume. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company was experiencing 'adoption challenges' and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight's products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Contact Us To Participate or Learn More: If you purchased RxSight securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at: Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Telephone: 310-914-5007 Email: [email protected] Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. View source version on CONTACT: Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Telephone: 310-914-5007 Email:[email protected] Visit our website at: KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Law Offices of Frank R. Cruz Copyright Business Wire 2025. PUB: 07/23/2025 12:03 PM/DISC: 07/23/2025 12:03 PM

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store